Emerald Advisers Inc. PA bought a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 22,132 shares of the company’s stock, valued at approximately $1,122,000.
Other hedge funds have also made changes to their positions in the company. Crossmark Global Holdings Inc. bought a new position in Ionis Pharmaceuticals in the third quarter valued at about $254,000. First Trust Advisors LP boosted its holdings in Ionis Pharmaceuticals by 40.2% in the third quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock valued at $49,805,000 after acquiring an additional 281,733 shares during the last quarter. Boston Advisors LLC boosted its holdings in Ionis Pharmaceuticals by 15.4% in the third quarter. Boston Advisors LLC now owns 6,875 shares of the company’s stock valued at $349,000 after acquiring an additional 915 shares during the last quarter. Fox Run Management L.L.C. bought a new position in Ionis Pharmaceuticals in the third quarter valued at about $294,000. Finally, Intl Fcstone Inc. bought a new position in Ionis Pharmaceuticals in the second quarter valued at about $598,000. Institutional investors own 88.98% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.truebluetribune.com/2017/11/14/emerald-advisers-inc-pa-takes-position-in-ionis-pharmaceuticals-inc-ions.html.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) opened at $54.84 on Tuesday. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21. The firm has a market capitalization of $6,820.00, a P/E ratio of 372.53 and a beta of 2.89. Ionis Pharmaceuticals, Inc. has a one year low of $37.26 and a one year high of $65.51.
In other news, SVP Patrick R. O’neil sold 1,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $58.35, for a total transaction of $58,350.00. Following the completion of the transaction, the senior vice president now directly owns 11,433 shares in the company, valued at approximately $667,115.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Richard S. Geary sold 8,268 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, October 13th. The stock was sold at an average price of $60.00, for a total value of $496,080.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 98,636 shares of company stock valued at $5,723,915. Corporate insiders own 2.13% of the company’s stock.
Several equities analysts recently issued reports on IONS shares. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a report on Monday, July 31st. Goldman Sachs Group, Inc. (The) reiterated a “sell” rating and issued a $30.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, October 6th. Needham & Company LLC reissued a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a research note on Sunday, September 17th. Barclays PLC assumed coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 target price on the stock. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $50.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $50.31.
Ionis Pharmaceuticals Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.